Abiraterone Acetate

醋酸阿比特龙

Report date: 2026/05/12 20:00:17
NMEFirst In Class

Base Information

Drug NameAbiraterone Acetate
Drug Alias Name乙酸阿比特龙酯Abiraterona阿比特隆Abiraterone acetate fine particleAbirateronum +[22] 
ClassificationSmall molecules > SteroidsSmall molecules > Prodrug
Mechanisms of ActionSteroid 17-alpha-hydroxylase inhibitors
TargetsSteroid 17-alpha-hydroxylase
Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsHormone-Resistant Prostate NeoplasmsRenal Insufficiency +[7] 
Global Approved IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Approved Indications in ChinaProstatic Neoplasms, Castration-Resistant
Original Approved Country/TerritoryUnited States
Original Approved Date2011/04/28
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineJanssen-Cilag International NvHunan Huize Biomedical Technology Co Ltd +[13] 
Inactive CompaniesRadboud University Medical CenterUniversity Of California San FranciscoUniversity of Texas Southwestern Medical Center +[15] 
Active IndicationsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsHormone-Resistant Prostate NeoplasmsRenal InsufficiencyAdrenal Hyperplasia, Congenital +[4] 

Other Information

ATC CodeL02BX03
Related LinksWikipediaDrugBankKEGG